We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Way to Identify Influenza A Virus Could Pave Way for More Sensitive Tests

By LabMedica International staff writers
Posted on 08 Jun 2022

The influenza A virus, which is responsible for seasonal flu outbreaks, causes between 290,000 and 650,000 deaths per year globally. More...

Because the influenza A virus is constantly changing, or mutating, it can be difficult to detect, treat, and inoculate against. To solve this problem, researchers are looking for parts of the influenza virus that do not change when the virus mutates. A panhandle structure on the virus known as the promoter region or promoter has emerged as a potential target. By finding new ways to target specific parts of the influenza A virus that do not change when the virus mutates, this research could be used to create more sensitive tests that can detect the influenza A virus more easily.

In order to quickly detect the presence of the influenza A virus, researchers at Tohoku University (Sendai, Japan) have developed a fluorogenic probe that could bind to the promoter region of the influenza A virus RNA. A fluorogenic probe is based on small molecules called fluorophores that emit light when a specific target is present. In the new study, the fluorogenic probe researchers created binds to part of the promoter region that consists of double-strand RNA structure carrying the internal loop, creating a significant light-up response that can identify the presence of influenza A. In order to create the fluorogenic probe, researchers used a type of synthetic DNA called peptide nucleic acid (PNA). The triplex-forming PNA can be specifically developed to target the double-stranded RNA in the panhandle structure of the influenza A virus RNA in the sequence-selective manner. Researchers then combined the triplex forming PNA having a type of dye called thiazole orange with a small molecule that would bind with the internal loop structure of the RNA.

This combination is called a conjugate. To determine how effective the conjugate was, researchers first analyzed how brightly the conjugate glowed when it was bound to the target panhandle structure of the promoter region. It was more than 130-fold brighter than when it was not bound to anything. Compared to the small molecules alone, the combination of the PNA and the small molecules had a stronger binding affinity by two orders of magnitude. This result shows how promising this technique could be for the diagnosis of influenza A, since the promoter region remains stable no matter the strain of influenza. In the future, this could even be a promising target for antiviral drugs that could treat infections of influenza A.

"The promoter region of influenza A virus RNA has emerged as a new target for biochemical and therapeutic application because the sequences are not involved in the gene variations related to pathogenesis (how the flu virus develops) and antiviral resistance," said Yusuke Sato, an associate professor at Tohoku University. "These results represent the development of new molecular probes for influenza A research, with a view toward the diagnosis of influenza A infection, as well as the design of new antivirus drugs targeting the influenza A virus RNA promoter region."

"The research group demonstrated the selective fluorescence response of the conjugate for total RNA from influenza A virus H1N1-infected cells over that from mock-infected ones," added Sato. "This technique would serve as a promising candidate for the analysis of influenza A virus RNA based on the direct sensing of the influenza A virus RNA promoter region, in sharp contrast to the gold standard PCR method."

Related Links:
Tohoku University 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.